Chemotherapy-induced peripheral neuropathy causes persistent numbness, tingling, pain and balance problems that reduce quality of life and daily functioning. Relevance stems from widespread use of neurotoxic agents such as platinum compounds, taxanes and vinca alkaloids; consequences include fall risk, dose reductions that can affect cancer outcomes, and long-term disability. Evidence on complementary approaches is mixed, so clinical guidance emphasizes careful selection and integration with oncology care.
Acupuncture and related therapies
Several clinical trials and systematic reviews suggest acupuncture may reduce pain and improve function for some survivors with chemotherapy-induced peripheral neuropathy. The American Society of Clinical Oncology guideline led by Charles L. Loprinzi Mayo Clinic notes limited but promising data for acupuncture and recommends discussing it as an option when standard treatments are inadequate. The National Center for Complementary and Integrative Health highlights acupuncture’s safety profile when administered by trained practitioners and its cultural roots in Chinese medicine, which may affect acceptance and expectations among different patient communities. Access to certified acupuncturists varies geographically, and cost or insurance coverage can limit uptake.
Exercise, cryotherapy, supplements and neuromodulation
Structured exercise programs combining aerobic and resistance training show modest, consistent benefits for neuropathic symptoms, balance and function in randomized and observational studies; these interventions also address fatigue and cardiovascular health, making them broadly beneficial. Local cooling of hands and feet during infusion (cryotherapy) has reduced neuropathy in some trials for taxane chemotherapy but can be poorly tolerated and is not universally applicable. Common supplements such as vitamin E and glutamine have produced inconsistent results; authoritative bodies advise caution because of limited efficacy data and potential interactions with cancer therapies. Emerging neuromodulation approaches including transcutaneous electrical nerve stimulation and device-based therapies have small trials suggesting symptom relief, but evidence quality remains low.
Clinical decisions should prioritize safety, symptom goals and integration with standard care. The National Cancer Institute recommends discussing complementary therapies with oncology teams to avoid interactions and to coordinate care. For many survivors, a combined approach—exercise, symptom-directed therapies such as acupuncture, and evidence-based pharmacologic options when needed—balances potential benefit and harm. Cultural preferences, insurance coverage and regional availability shape what is feasible for individual patients, so personalized discussion and referral to credentialed practitioners are essential.